Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia

(2018) Pieter T. de Boer et al.   VACCINE

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

(2017) Viviane Gresset-Bourgeois et al.   Expert Review of Vaccines

A systematic review of the health economic consequences of quadrivalent influenza vaccination

(2017) Pieter T. de Boer et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

(2016) Stephanie Pepin et al.   Human Vaccines & Immunotherapeutics

Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial

(2015) Josefina B. Cadorna-Carlos et al.   VACCINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

(2013) Stéphanie Pépin et al.   VACCINE

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Vaccine presentation in the USA: economics of prefilled syringes versus multidose vials for influenza vaccination

(2010) Claudia C Pereira et al.   Expert Review of Vaccines